scholarly journals Paraneoplastic Cerebellar Degeneration with Anti-CV2/CRMP5 Antibodies in Ovarian Cancer: Case Report and Review of the Literature

2021 ◽  
pp. 1799-1805
Author(s):  
Juan José Juárez-Vignon Whaley ◽  
Aurelio Carrera-Muiños ◽  
Karol Gema Hernandez-Gutierrez ◽  
Jerónimo Rafael Rodriguez-Cid ◽  
Maria Elisa Otero-Cerdeira ◽  
...  

Paraneoplastic neurological syndromes (PNS) are rare presentations of an underlying oncological disease and more unusual during an oncological disease. They most likely present in small-cell lung carcinomas and thymomas, but present in <1% of the gynecological neoplasms. Acknowledging the pathophysiology is essential for management, explaining its clinical presentation, and future research. We present a patient with an underlying gynecological cancer that during her disease developed a PNS with an unusual autoantibody (anti-CV2/CRMP5) mediating the disease. We report a case of a 62-year-old female diagnosed with ovarian cancer who in the course of her disease developed neurological symptoms associated with cerebellar degeneration. After ruling out differential diagnoses such as metastases, a PNS was suspected and studied, in which anti-CV2/CRMP5 antibodies were positive. With her clinical presentation, radiological features, autoantibody positivity on cerebrospinal fluid, and an underlying oncological disease, cerebellar degeneration was diagnosed. The pathophysiology of PNS is not fully understood; therefore, its diagnosis and management are complex. Diagnosis is based on clinical presentation and specific antibodies associated. Unfortunately, patients have a bad prognosis and diminished quality of life, and therefore a multidisciplinary approach is needed. It is important to mention that the presentation of PNS does not mandatorily appear before the diagnosis of cancer, and multiple cases have been reported in which patients with an underlying oncological disease develop these syndromes. As medical oncologists and neurologists, we must consider and study these syndromes as a possible etiology in cases with an underlying cancer who develop neurological symptoms in the course of their disease.

2021 ◽  
Author(s):  
Juan Jose Juarez-Vignon Whaley ◽  
Aurelio Carrera-Muiños ◽  
Karol Gema Hernandez-Gutierrez ◽  
Jerónimo Rafael Rodriguez-Cid ◽  
Maria Elisa Otero-Cerdeira ◽  
...  

Abstract BackgroundParaneoplastic neurological syndromes are rare presentations of an underlying oncological disease and even more unusual they can present during an oncological disease. These syndromes more likely present in small cell lung carcinomas and thymomas, but in less than 1% of the cases gynecological neoplasms have shown this paraneoplastic presentation, such as the case presented. Even though not completely understood yet, acknowledging the pathophysiology is essential for management, relate other types of neoplasms and explain its clinical presentation. We present a patient with an underlying gynecological cancer, that during her disease developed a paraneoplastic neurological syndrome with an unusual autoantibody (anti-CV2/CRMP5) mediating the disease.Case PresentationA 62-yo female diagnosed with ovarian cancer who in the course of her disease develops neurological symptoms associated with cerebellar degeneration. After ruling out differential diagnoses such as metastases, a neurological paraneoplastic syndrome was suspected and studied, in which anti-CV2/CRMP5 were positive. Putting together her clinical presentation, radiological features, auto-antibody positivity on CSF related with paraneoplastic neurological syndromes and an underlying oncological disease, cerebellar degeneration as a paraneoplastic syndrome was diagnosed.ConclusionThe pathophysiology of neurological paraneoplastic syndromes is not fully understood; therefore, its diagnosis and management are complex. Diagnosis is based on clinical presentation and specific antibodies associated. Unfortunately, patients have a bad prognosis and diminished quality of life, therefore its management needs a multidisciplinary approach. It is important to mention that the presentation of paraneoplastic neurological syndromes do not mandatory appear before the diagnosis of cancer, multiple cases have been reported in which patients with an underlying oncological disease develop these syndromes. As medical oncologists and neurologists we must consider and study these syndromes as a possible etiology in cases with an underlying cancer who develop neurological symptoms in the course of their disease after ruling out differential diagnoses such as brain metastases.


2020 ◽  
pp. 100695
Author(s):  
Sandra Deac ◽  
Mihaela Marioara Stana ◽  
Andrei Dan Havasi ◽  
Cainap Calin ◽  
Anca-Raluca Popita ◽  
...  

2019 ◽  
Vol 18 (11) ◽  
pp. 2191-2206 ◽  
Author(s):  
Róisín O'Flaherty ◽  
Mohankumar Muniyappa ◽  
Ian Walsh ◽  
Henning Stöckmann ◽  
Mark Hilliard ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
K. N Srinivasan ◽  
Amit Rauthan ◽  
R. Gopal

Background. Ovarian cancer is the ninth most common cancer among women and causes more deaths than any other type of female reproductive cancer. Albumin-bound paclitaxel is known to increase intratumoral concentration of the paclitaxel by a receptor-mediated transport process across the endothelial cell wall, thereby breaching the blood/tumor interface. We present below three cases in which nab-paclitaxel based chemotherapy has been used in different settings for patients with ovarian cancer.Case Presentation. In the first case nab-paclitaxel was used along with carboplatin in adjuvant setting, in the second case, nab-paclitaxel was used along with carboplatin and bevacizumab as second line chemotherapy in a relapsed ovarian cancer case, and the third case delineates the use of nab-paclitaxel along with cisplatin as third line chemotherapy.Conclusion. In all the three scenarios, patients tolerated the chemotherapy well, as well as responding well to nab-paclitaxel based chemotherapy. The patients are currently on long-term follow-up and have been having an uneventful postchemotherapy.


2020 ◽  
Vol 33 ◽  
pp. 100606
Author(s):  
Ricardo Pedrini Cruz ◽  
Gustavo Peretti Rodini ◽  
Margarete Duarte da Rosa ◽  
Vinicius Duarte Cabral ◽  
Eduardo Cambruzzi ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (5) ◽  
pp. e35235 ◽  
Author(s):  
Paola Raska ◽  
Edwin Iversen ◽  
Ann Chen ◽  
Zhihua Chen ◽  
Brooke L. Fridley ◽  
...  

2017 ◽  
Vol 6 (1) ◽  
pp. 43-47
Author(s):  
Przemysław Hubert Krawczyk ◽  
Marcin Braun ◽  
Dariusz Kaczmarczyk

Increase in the occurrence of multiple primary malignant tumours is associated with significant extention of survival rate among patients treated for malignant neoplasm. Treatment of multiple primary malignant tumours demands precise clinical evaluation, imaging, laboratory diagnostics and histopathological evaluation of the lesion. In the presented case immunohistochemical staining of lymphatic metastasis from nasopharyngeal carcinoma was mimicking distant metastasis from poorly differentiated ovarian cancer. It impeded histopathological diagnosis and required additional imaging enriched by PET-CT, which allowed the visualization of the second tumor.


A lady discovered she had ovarian cancer in 2016 and was treated by CellSonic. The tumour remained big and had to be surgically removed after the cancer was stopped. Since then, cancer diagnostics have progressed and the electrical properties can now be easily detected allowing CellSonic to advance from stopping cancer in a patient to stopping cancer in a population. The patient is well and has approved this article.


2021 ◽  
Vol 05 (06) ◽  
pp. 68-71
Author(s):  
Emilio M Treviño-Salinas ◽  
Andrés Murillo-Mendoza ◽  
Abel Guzmán-López ◽  
Juan A SoriaLópez ◽  
Nancy M Dávila-Flores

Sign in / Sign up

Export Citation Format

Share Document